This review is a summary of evidence in support of febuxostat (Adenuric®) in the treatment of hyperuricaemia in patients with gout. Febuxostat is an orally-administered xanthine oxidase inhibitor that blocks the production of uric acid. In Australia, febuxostat is indicated for the treatment of chronic symptomatic hyperuricaemia in conditions where urate deposition has already occurred (gouty arthritis and/or tophus formation) in adults with gout.
Please login below to download this issue (PDF)